Cynata Therapeutics
Australia - CremorneBiotechnology
Focus: Cynata Therapeutics is a stem cell manufacturing technology company focused on developing cell therapy products using induced pluripotent stem cell (iPSC) platforms. The company is based in Australia and operates as a pre-revenue biotech with an early-stage pipeline.
Profile data last refreshed 4d ago · AI intelligence enriched 2w ago
Open Jobs
0
About Cynata Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Cynata Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Mesenchymoangioblast-derived mesenchymal stem cells
Graft vs Host DiseaseClinical Trials (1)
NCT02923375A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease
Phase 1Help build intelligence for Cynata Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.